# PP-0188 — Molecular Subtypes of Gastric Cancer
## QA Report

**QA ID:** QA-PP-0188  
**PP ID:** PP-0188  
**Version:** 1.0.0  
**Status:** PASS — GOLD — READY FOR INTEGRATION  
**Last Updated:** 2026-08-09

---

# 1. QA Executive Summary

PP-0188 was produced after the complete Decision Batch for **Molecular Subtypes of Gastric Cancer** was approved and locked.

The Gold package contains:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

The package follows the locked Gold Population Package Specification v1.0 and the project working rules.

**Overall QA Decision: PASS — GOLD — READY FOR INTEGRATION.**

---

# 2. Layer 1 — Content QA

## 2.1 Scope respected

**PASS**

The CKO is centered on one atomic educational question:

> What major molecular-subtyping frameworks exist in gastric cancer, what do they mean, how do TCGA and ACRG compare, and what is their clinical significance?

The content is restricted to:

- TCGA;
- ACRG;
- subtype biology;
- selected clinical associations;
- cross-framework comparison;
- implementation limits.

---

## 2.2 TCGA completeness

**PASS**

All four major TCGA subtypes are represented:

- EBV;
- MSI;
- GS;
- CIN.

Each receives:

- definition;
- biological context;
- clinical relevance;
- appropriate evidence qualification.

---

## 2.3 ACRG completeness

**PASS**

All four ACRG subtypes are represented:

- MSI;
- MSS/EMT;
- MSS/TP53+;
- MSS/TP53−.

Each receives:

- definition;
- biological context;
- clinical phenotype;
- prognosis/recurrence context where supported.

---

## 2.4 TCGA–ACRG comparison completeness

**PASS — CRITICAL**

The package explicitly includes:

- overlap;
- broad enrichment relationships;
- non-one-to-one mapping;
- GS vs MSS/EMT distinction;
- EBV vs MSS/TP53+ distinction;
- CIN vs MSS/TP53− distinction;
- explanation of different classification inputs.

This is a mandatory core feature of PP-0188.

---

## 2.5 Clinical boundary completeness

**PASS**

The package distinguishes:

- molecular subtype;
- individual biomarker;
- Lauren classification;
- TNM stage;
- treatment selection.

No major ownership collision identified.

---

# 3. Layer 2 — Clinical QA

## 3.1 Clinical accuracy

**PASS**

Major subtype definitions and clinical associations are consistent with the supplied TCGA and ACRG source papers.

---

## 3.2 Evidence qualification

**PASS**

The package distinguishes:

### Strong / replicated

- molecular subtype definitions;
- cohort-level prognosis associations;
- ACRG recurrence patterns;
- TCGA–ACRG overlap/non-equivalence.

### Exploratory / retrospective

- TCGA subtype-specific chemotherapy benefit.

### Not established

- universal routine subtype testing;
- subtype-only treatment selection;
- individualized subtype-based prognosis.

---

## 3.3 Treatment safety

**PASS**

No routine treatment prescription is made from molecular subtype alone.

The TCGA chemotherapy finding is explicitly labeled retrospective/hypothesis-generating.

---

## 3.4 Prognostic safety

**PASS**

The package uses cohort-level language:

- “associated with”;
- “reported in validation cohorts”;
- “population-level association.”

It does not convert subtype membership into an individualized survival prediction.

---

## 3.5 Biomarker safety

**PASS**

The package clearly states:

> molecular subtype ≠ individual biomarker.

It avoids automatically equating:

- TP53 mutation with MSS/TP53−;
- EBV positivity with MSS/TP53+;
- GS with MSS/EMT;
- CIN with MSS/TP53−.

---

# 4. Layer 3 — Educational QA

## 4.1 Patient-centered framing

**PASS**

The package begins with the concept of molecular subtype and explains why it matters before introducing technical terminology.

---

## 4.2 Terminology

**PASS**

Terms are expanded on first use:

- EBV;
- MSI;
- GS;
- CIN;
- EMT;
- TP53.

---

## 4.3 Concept hierarchy

**PASS**

The package uses the following hierarchy:

**Cancer heterogeneity**
→ **molecular classification**
→ **TCGA / ACRG**
→ **subtypes**
→ **clinical associations**
→ **limitations**

This is appropriate for patient education.

---

## 4.4 Common misconception control

**PASS**

The package explicitly addresses:

- TCGA vs ACRG equivalence;
- subtype vs biomarker;
- subtype vs histology;
- subtype vs stage;
- subtype vs treatment selection;
- subtype vs individualized prognosis.

---

## 4.5 Cognitive load

**PASS**

The content is divided into independent Clinical Knowledge Blocks rather than one continuous narrative.

---

# 5. Layer 4 — Governance QA

## 5.1 Gold artifact structure

**PASS**

Required artifacts are present:

- CKO;
- Knowledge Passport;
- Primary Evidence Package;
- QA Report.

---

## 5.2 Naming

**PASS**

Required filenames:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

## 5.3 Versioning

**PASS**

All artifacts use:

**Version 1.0.0**

---

## 5.4 Boundary

**PASS**

A single clean Boundary declaration is included in each artifact where appropriate, and the production response declares the final Boundary once.

Boundary structure:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

---

## 5.5 Knowledge Graph

**PASS**

The package identifies:

- prerequisite PPs;
- related PPs;
- downstream PPs.

---

## 5.6 Evidence traceability

**PASS**

Primary evidence is explicitly mapped to:

- TCGA foundational evidence;
- Sohn clinical validation;
- ACRG molecular classification;
- current guideline anchor.

---

# 6. Source Integrity QA

## S1 — TCGA Clinical Validation

**PASS**

Claims about:

- EBV/MSI/GS/CIN;
- prognosis;
- recurrence-free survival;
- adjuvant chemotherapy;
- TRS;

are attributed to the Sohn et al. study.

---

## S2 — ACRG

**PASS**

Claims about:

- MSI;
- MSS/EMT;
- MSS/TP53+;
- MSS/TP53−;
- prognosis;
- recurrence;
- peritoneal recurrence;
- TCGA comparison;

are attributed to the Cristescu et al. study.

---

## Current guideline anchoring

**PASS WITH SCOPE LIMIT**

NCCN is used as the current clinical anchor.

The detailed molecular-subtype claims remain grounded in the primary TCGA/ACRG research papers rather than being incorrectly represented as current NCCN subtype recommendations.

---

# 7. Boundary QA

## Core

**PASS**

Core ownership is limited to molecular-subtyping frameworks and their clinical meaning.

## Supporting

**PASS**

Supporting material does not become independent biomarker packages.

## Explicitly Excluded

**PASS**

Technical testing, treatment algorithms, individualized prognosis, and detailed adjacent content are excluded.

## Delegated-to PP

**PASS**

The major adjacent molecular-testing packages are explicitly delegated.

---

# 8. Overlap QA

| Adjacent PP | Risk | Resolution | Status |
|---|---|---|---|
| PP-0178 Histopathologic Classification | pathology overlap | PP-0188 uses only contextual relationship | PASS |
| PP-0179 Lauren Classification | intestinal/diffuse overlap | PP-0179 owns detailed histology; PP-0188 owns molecular relationship | PASS |
| PP-0180 Molecular Classification | conceptual overlap | PP-0180 owns high-level molecular-classification concept; PP-0188 owns major subtype frameworks | PASS |
| PP-0168 EBV | EBV overlap | PP-0168 owns EBV disease/testing; PP-0188 owns EBV as TCGA subtype | PASS |
| PP-0182 MSI/MMR | MSI overlap | PP-0182 owns testing; PP-0188 owns MSI as subtype | PASS |
| PP-0181 HER2 | molecular biology overlap | PP-0181 owns HER2 testing | PASS |
| PP-0183 PD-L1 | immune biology overlap | PP-0183 owns PD-L1 testing | PASS |
| PP-0184 CLDN18.2 | biomarker overlap | PP-0184 owns CLDN18.2 testing | PASS |
| PP-0185 TMB | mutation burden overlap | PP-0185 owns TMB | PASS |
| PP-0186 FGFR2 | genomic alteration overlap | PP-0186 owns FGFR2 testing | PASS |
| PP-0187 NGS | molecular-data overlap | PP-0187 owns NGS biomarker testing | PASS |
| PP-0189 Genomic Test Results | report interpretation overlap | PP-0189 owns interpretation | PASS |
| PP-0190 Targeted Therapy Testing | treatment selection overlap | PP-0190 owns treatment-relevant testing | PASS |
| PP-0191 Immunotherapy Testing | treatment selection overlap | PP-0191 owns treatment-relevant testing | PASS |

---

# 9. Safety QA

## Unsafe treatment recommendation

**NONE**

## Unsupported individualized prognosis

**NONE**

## Overclaim of routine molecular-subtype testing

**NONE**

## False equivalence of TCGA and ACRG

**NONE**

## Biomarker/subtype conflation

**NONE**

## Stage/subtype conflation

**NONE**

---

# 10. Internal Consistency QA

### CKO ↔ KP

**PASS**

Scope, boundary, and Knowledge Graph are aligned.

### CKO ↔ Evidence Package

**PASS**

Clinical Knowledge Blocks are traceable to the Evidence Package.

### Evidence Package ↔ QA

**PASS**

QA conclusions reflect the evidence classification.

### Boundary ↔ Registry architecture

**PASS**

Boundary aligns with adjacent PP structure.

---

# 11. Completeness Matrix

| Required Gold Component | Present | Status |
|---|---:|---|
| Metadata | Yes | PASS |
| Educational Objectives | Yes | PASS |
| Scope | Yes | PASS |
| Included | Yes | PASS |
| Not Included | Yes | PASS |
| Clinical Knowledge Blocks | Yes | PASS |
| Patient Explanation | Yes | PASS |
| Clinical Importance | Yes | PASS |
| Key Concepts | Yes | PASS |
| Common Misconceptions | Yes | PASS |
| Key Messages | Yes | PASS |
| Knowledge Graph | Yes | PASS |
| Prerequisite PP | Yes | PASS |
| Related PP | Yes | PASS |
| Next PP | Yes | PASS |
| Revision History | Yes | PASS |
| Evidence Matrix | Yes | PASS |
| Evidence Gaps | Yes | PASS |
| Future Update Triggers | Yes | PASS |
| Boundary | Yes | PASS |
| Four-layer QA | Yes | PASS |

---

# 12. Final QA Decision

## **PASS — GOLD — READY FOR INTEGRATION**

No critical blocker identified.

No architecture blocker identified.

No unresolved clinical-scope blocker identified.

No evidence-traceability blocker identified.

No major overlap blocker identified.

---

# 13. Final Boundary

**Core = major molecular-subtyping frameworks of gastric cancer; TCGA and ACRG classification systems; subtype definitions; biological characteristics; key clinical/prognostic and recurrence associations; comparison and non-equivalence of TCGA and ACRG; relationship of molecular subtype to histology, stage, and individual biomarkers; research-versus-clinical implementation distinction.**

**Supporting = immune biology, genomic instability, selected gene examples, recurrence-pattern context, exploratory treatment-response evidence, molecular heterogeneity and precision-oncology context.**

**Explicitly Excluded = detailed histopathology/WHO/Lauren classification, individual biomarker assay methodology, NGS technical methodology, variant interpretation, genomic-report interpretation, detailed subtype prediction algorithms, universal TCGA/ACRG testing, individualized prognosis, subtype-specific treatment prescription, routine subtype-guided chemotherapy/immunotherapy, hereditary/germline classification, longitudinal molecular monitoring.**

**Delegated-to PP = PP-0168, PP-0181, PP-0182, PP-0183, PP-0184, PP-0185, PP-0186, PP-0187, PP-0189, PP-0190, PP-0191, and relevant treatment Population Packages.**

---

# 14. Repository Readiness

**Repository status: READY FOR INTEGRATION**

Required artifact set is complete and internally consistent.

**Final QA status: PASS — GOLD — READY FOR INTEGRATION.**
